Purpose Erlotinib (ETB) is a well-established therapeutic for non-small-cell lung cancer
(NSCLC). To overcome drug resistance and severe toxicities in the clinical application …

Background Aim of this study was to prepare the hyaluronic acid and human serum albumin
modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a precipitation …

Erlotinib-based EGFR targeted therapy has proven significant clinical improvement against
non-small cell lung cancer (NSCLC). However, the anticancer activity of Erlotinib (Ertb) is …

Poor water solubility and low oral bioavailability limit the clinical application of Erlotinib as
an anticancer. For this purpose, we encapsulated erlotinib in the solid lipid nanoparticles …

This study was aimed at developing a nanoparticle strategy to overcome acquired
resistance against erlotinib in non-small cell lung cancer (NSCLC). To load erlotinib on …

Non-small cell lung cancer (NSCLC) is a global concern as one of the leading causes of
cancer deaths. The treatment options for NSCLC are limited to systemic chemotherapy …

We have investigated the effects of combination treatment involving ERL (erlotinib) with a
glycyrrhetinic acid analog, CDODA-Me in overcoming ERL resistance, providing efforts to …

Background: Erlotinib (ELTN)-based targeted therapy as first-line treatment for epidermal
growth factor receptor (EGFR)-mutant lung cancers suffers from insufficient selectivity, side …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in
China. This study aimed to develop a hyaluronic acid (HA) decorated, pH sensitive lipid …

Core–shell type lipid–polymer hybrid nanoparticles (CSLPHNPs) have emerged as a
multifunctional drug delivery platform. The delivery system combines mechanical …